What every dentist should know about metformin, diabetes, and cancer
Abstract
Metformin has long been the drug of choice for treating patients with type 2 diabetes. Because of its effectiveness, safety profile, and affordability, it is used by millions of people worldwide. Emerging evidence indicates that metformin might also have antineoplastic effects in both diabetic and nondiabetic individuals. This article reviews studies that examine the potential mechanisms of action underlying the anticancer properties of metformin and discusses the possible use of this antidiabetic biguanide in the chemoprevention and treatment of head and neck cancer.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.